Updated on 2025/03/29

写真a

 
MATSUZAKI Tetsuo
 
Organization
Nagoya University Hospital Department of Hospital Pharmacy Designated assistant professor
Title
Designated assistant professor

Research Areas 3

  1. Life Science / Function of nervous system

  2. Life Science / Cell biology

  3. Life Science / Molecular biology

Research History 3

  1. Nagoya University Hospital   Hospital Pharmacy, Department of Neuropsychopharmacology   Designated assistant professor

    2022.4

  2. Nagoya University Hospital   Hospital Pharmacy

    2019.4 - 2022.3

  3. Japan Society for the Promotion of Science

    2018.4 - 2019.3

Education 2

  1. The University of Tokyo   Graduate School of Pharmaceutical Sciences

    2015.4 - 2019.3

      More details

    Country: Japan

  2. The University of Tokyo   Faculty of Pharmaceutical Sciences   Department of Pharmacy

    2010.4 - 2015.3

      More details

    Country: Japan

Professional Memberships 4

  1. 日本化学療法学会

    2022.1

  2. 日本医療薬学会

    2019.4

  3. 日本病院薬剤師会

    2019.4

  4. 日本分子生物学会

    2014.7

Committee Memberships 3

  1. 一般社団法人東海地区調整機構   実務実習契約・施設概要更新小委員会  

    2024.4   

      More details

    Committee type:Other

  2. 愛知県病院薬剤師会   薬学生病院実習検討委員会  

    2022.4   

      More details

    Committee type:Academic society

  3. 国立研究開発法人日本医療研究開発機構   医薬品等規制調和・評価研究事業「乱用防止に資する医薬品の開発のための製剤学的アプローチ に関する研究」  

    2019.7 - 2022.3   

      More details

    Committee type:Government

Awards 1

  1. 第141回日本薬理学会近畿部会最優秀発表賞

    2022.7   Phosphorylation of twinfilin-1 involved in the reelin signaling plays a crucial role in spine development

    Geyao Dong, Norimichi Itoh, Tetsuo Matsuzaki, Hiroyuki Mizoguchi, Daisuke Mori, Taku Nagai, Toshitaka Nabeshima, Norio Ozaki, Kiyofumi Yamada

 

Papers 10

  1. The Use of Text Mining to Obtain a Historical Overview of Research on Therapeutic Drug Monitoring Reviewed Open Access

    Tetsuo Matsuzaki, Hiroyuki Mizoguchi, Kiyofumi Yamada

    Biological and Pharmaceutical Bulletin   Vol. 47 ( 11 ) page: 1883 - 1892   2024.11

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Pharmaceutical Society of Japan  

    <p>Therapeutic drug monitoring (TDM) is a routine clinical practice used to individualize drug dosing to maintain drug efficacy and minimize the consequences of overexposure. TDM is applied to many drug classes, including immunosuppressants, antineoplastic agents, and antibiotics. Considerable effort has been made to establish routine TDM practices for each drug. However, because TDM has been developed within the context of specific drugs, there is insufficient understanding of historical trends within the field of TDM research as a whole. In this study, we employed text-mining approaches to explore trends in the TDM research field. We first performed a PubMed search to determine which drugs and drug classes have been extensively studied in the context of TDM. This investigation revealed that the most commonly studied drugs are tacrolimus, followed by cyclosporine and vancomycin. With regard to drug classes, most studies focused on immunosuppressants, antibiotics, and antineoplastic agents. We also subjected PubMed records of TDM-related studies to a series of text-mining pipelines. Our analyses revealed how TDM research has evolved over the years, thereby serving as a cornerstone for forecasting future research trends.</p>

    DOI: 10.1248/bpb.b24-00319

    Open Access

    Web of Science

    Scopus

    PubMed

    CiNii Research

  2. A novel plasmid‐based experimental system in <i>Saccharomyces cerevisiae</i> that enables the introduction of 10 different plasmids into cells Reviewed Open Access

    Geyao Dong, Tsuyoshi Nakai, Tetsuo Matsuzaki

    FEBS Open Bio   Vol. 14 ( 12 ) page: 1955 - 1971   2024.10

     More details

    Authorship:Last author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Wiley  

    The budding yeast Saccharomyces cerevisiae is commonly used as an expression platform for the production of valuable compounds. Yeast‐based genetic research can uniquely utilize auxotrophy in transformant selection: auxotrophic complementation by an auxotrophic marker gene on exogenous DNA (such as plasmids). However, the number of required auxotrophic nutrients restricts the number of plasmids maintained by the cells. We, therefore, developed novel Δ10 strains that are auxotrophic for 10 different nutrients and new plasmids with two multiple cloning sites and auxotrophic markers for use in Δ10 strains. We confirmed that Δ10 strains were able to maintain 10 types of plasmids. Using plasmids encoding model proteins, we detected the co‐expression of 17 different genes in Δ10 cell lines. We also constructed Δ9 strains that exhibited auxotrophy for nine nutrients and increased growth compared to Δ10. This study opens a new avenue for the co‐expression of a large number of genes in eukaryotic cells.

    DOI: 10.1002/2211-5463.13893

    Open Access

    Web of Science

    Scopus

    PubMed

  3. Antipsychotic-like effects of the selective Rho-kinase 2 inhibitor KD025 in genetic and pharmacological mouse models of schizophrenia

    Rinako Tanaka, Jingzhu Liao, Yue Liu, Wenjun Zhu, Kisa Fukuzawa, Masamichi Kondo, Masahito Sawahata, Daisuke Mori, Akihiro Mouri, Hisayoshi Kubota, Daiki Tachibana, Yohei Kobayashi, Tetsuo Matsuzaki, Taku Nagai, Toshitaka Nabeshima, Kozo Kaibuchi, Norio Ozaki, Hiroyuki Mizoguchi, Kiyofumi Yamada

        2024.9

     More details

    Language:English   Publisher:Cold Spring Harbor Laboratory  

    1Abstract

    Copy number variations in theARHGAP10gene encoding Rho GTPase–activating protein 10 are significantly associated with schizophrenia. ARHGAP10 negatively regulates RhoA/Rho-kinase (ROCK) signaling. We previously demonstrated that fasudil, a non-selective ROCK inhibitor, exhibited antipsychotic-like effects in several mouse models of schizophrenia. ROCK has two subtypes, ROCK1 and ROCK2. ROCK1 is mainly expressed in the thymus and blood, while ROCK2 is predominantly expressed in the brain. Therefore, it is expected that like fasudil, selective ROCK2 inhibitors will exhibit antipsychotic-like effects, accompanied by a lower incidence of adverse effects due to ROCK1 inhibition. Here, we used genetic and pharmacological models of schizophrenia to investigate whether the selective ROCK2 inhibitor KD025 would show antipsychotic-like effects with a favorable adverse effect profile. Oral administration of KD025 suppressed the abnormal increase in the phosphorylation level of myosin phosphatase–targeting subunit 1, a substrate of ROCK, and ameliorated the decreased spine density of layer 2/3 pyramidal neurons in the medial prefrontal cortex ofArhgap10S490P/NHEJ mice. Furthermore, KD025 mitigated the methamphetamine-induced impairment of visual discrimination (VD) inArhgap10S490P/NHEJ and wild-type mice. KD025 also reduced MK-801–induced impairments of VD, novel object recognition, and hyperlocomotion. Regarding side effects that are commonly seen with typical antipsychotics, KD025 did not affect systolic blood pressure and did not induce extrapyramidal symptoms, hyperprolactinemia, or hyperglycemia at the effective dosage in naïve wild-type mice. Taken together, KD025 shows antipsychotic-like effects with a favorable adverse effect profile in genetic and pharmacological mouse models of schizophrenia.

    DOI: 10.1101/2024.09.16.613372

  4. Integration of pharmacists' knowledge into a predictive model for teicoplanin dose planning

    Tetsuo Matsuzaki, Tsuyoshi Nakai, Yoshiaki Kato, Kiyofumi Yamada, Tetsuya Yagi

        2023.12

     More details

    Publisher:Cold Spring Harbor Laboratory  

    Teicoplanin is an important antimicrobial agent for methicillin-resistant Staphylococcus aureus infections. To enhance its clinical effectiveness while preventing adverse effects, therapeutic drug monitoring (TDM) of teicoplanin trough concentration is recommended. Given the importance of the early achievement of therapeutic concentrations for treatment success, initial dosing regimens are deliberately designed based on patient information. Considerable effort has been dedicated to developing an optimal initial dose plan for specific populations; however, comprehensive strategies for tailoring teicoplanin dosing have not been successfully implemented. The initial dose planning of teicoplanin is conducted at the clinician's discretion and is thus strongly dependent on the clinician's experience and expertise. The present study aimed to use a machine learning (ML) approach to integrate clinicians' knowledge into a predictive model for initial teicoplanin dose planning. We first confirmed that dose planning by pharmacists dedicated to TDM (hereafter TDM pharmacists) significantly improved early therapeutic target attainment for patients without an intensive care unit or high care unit stay, providing the first evidence that dose planning of teicoplanin by experienced clinicians enhances early teicoplanin therapeutic exposure. Next, we used a dataset of teicoplanin initial dose planning by TDM pharmacists to train and implement the model, yielding a model that emulated TDM pharmacists' decision-making for dosing. We further applied ML to cases without TDM pharmacist dose planning and found that the target attainment rate of the initial teicoplanin concentration markedly increased. Our study opens a new avenue for tailoring the initial dosing regimens of teicoplanin using a TDM pharmacist-trained ML system.

    DOI: 10.1101/2023.12.14.23299934

  5. Overview of draft guidelines for the development of abuse-deterrent opioid formulations Reviewed

      Vol. 58 ( 2 ) page: 51 - 57   2023.12

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

▼display all

MISC 1

  1. AIと薬剤師業務 Invited

    松﨑 哲郎

    日本病院薬剤師会雑誌 = Journal of Japanese Society of Hospital Pharmacists   Vol. 60 ( 6 ) page: 573 - 577   2024.6

     More details

    Authorship:Lead author, Corresponding author   Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (other)   Publisher:東京 : 日本病院薬剤師会  

    CiNii Books

    Other Link: https://ndlsearch.ndl.go.jp/books/R000000004-I033556583

Presentations 31

  1. 知識ゼロからはじめる薬剤師業務へのAIの応用 Invited

    松﨑 哲郎

    第29回鳥取県医療薬学セミナー  2024.12.8 

     More details

    Event date: 2024.12

    Presentation type:Oral presentation (invited, special)  

  2. 多種類遺伝子発現を実現する新規出芽酵母実験系の樹立とその改良

    松﨑 哲郎, Geyao Dong, 中井剛

    日本病院薬剤師会東海ブロック・日本薬学会東海支部合同学術大会2024  2024.10.27 

     More details

    Event date: 2024.10

    Presentation type:Oral presentation (general)  

  3. 最大10種類のプラスミドを保持できる新規出芽酵母遺伝学実験系の樹立

    松﨑 哲郎, Geyao Dong, 中井 剛

    日本薬学会第144年会  2024.3.30 

     More details

    Event date: 2024.3

    Language:Japanese   Presentation type:Oral presentation (general)  

  4. 最大10種類のプラスミドを保持できる新規出芽酵母遺伝学実験系の樹立

    松﨑 哲郎, Geyao Dong, 中井 剛

    日本病院薬剤師会東海ブロック・日本薬学会東海支部合同学術大会2023  2023.11.12 

     More details

    Event date: 2023.11

    Presentation type:Oral presentation (general)  

  5. 最大10種類のプラスミドを保持できる新規出芽酵母遺伝学実験系の樹立

    Geyao Dong, 中井剛, 松﨑哲郎

    第69回 日本薬学会東海支部大会  2023.7.8 

     More details

    Event date: 2023.7

    Language:Japanese   Presentation type:Oral presentation (general)  

▼display all

Other research activities 2

  1. 一般社団法人日本病院薬剤師会 病院薬学認定薬剤師

    2024.7

  2. 一般社団法人薬学教育協議会 認定実務実習指導薬剤師

    2024.4

KAKENHI (Grants-in-Aid for Scientific Research) 7

  1. バイオマスからの有用化学物質産生に資する出芽酵母多種類遺伝子発現系の構築

    Grant number:24K17995  2024.4 - 2026.3

    日本学術振興会  科学研究費助成事業  若手研究

    松崎 哲郎

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

  2. 専門家知識を組み込んだ抗MRSA薬初期投与設計用人工知能の構築

    2024.4 - 2025.3

    一般財団法人 中京長寿医療研究推進財団  令和5年度医学研究助成 

    松﨑 哲郎

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\300000 ( Direct Cost: \300000 )

  3. 出芽酵母新規タンパク質発現系を応用した抗生剤生合成経路の樹立

    2023.9 - 2024.8

    公益財団法人 杜の都医学振興財団  2023年度 研究助成金 

      More details

    Authorship:Principal investigator  Grant type:Competitive

    Grant amount:\500000 ( Direct Cost: \500000 )

  4. Study on the regulation mechanism of neural spine morphology and cognitive function by twinfilin-1

    Grant number:23H02669  2023.4 - 2026.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

      More details

    Authorship:Coinvestigator(s) 

  5. Study on the regulation mechanism of neural spine morphology and cognitive function by twinfilin-1

    Grant number:23K27360  2023.4 - 2026.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

▼display all

 

Teaching Experience (Off-campus) 3

  1. Pharmacy clinical training program (hospital)

    2022.4 Nagoya University Hospital)

  2. ベーシックトレーニング (名古屋大学大学院医学系研究科)

    2022.4

  3. 基礎医学セミナー (名古屋大学医学部)

    2022.4